# A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

> **NCT06092268** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 270 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** SHR-A2009 for injection ； Almonertinib Mesilate Tablets
- **DRUG:** SHR-A2009 for injection；Adebrelimab Injection

## Key facts

- **NCT ID:** NCT06092268
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06092268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06092268, "A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06092268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*